Blenrep (belantamab mafodotin-blmf) vs Tecvayli (teclistamab-cqyv)
Blenrep (belantamab mafodotin-blmf) vs Tecvayli (teclistamab-cqyv)
Blenrep (belantamab mafodotin-blmf) is an antibody-drug conjugate specifically targeting B-cell maturation antigen (BCMA) for the treatment of relapsed or refractory multiple myeloma in patients who have received at least four prior therapies. Tecvayli (teclistamab-cqyv) is a bispecific T-cell engager that also targets BCMA but works by redirecting T cells to eliminate myeloma cells and is indicated for the treatment of relapsed or refractory multiple myeloma in adults after at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The choice between Blenrep and Tecvayli should be made in consultation with a healthcare provider, considering the individual patient's medical history, prior treatments, potential side effects, and the mechanism of action of each medication.
Difference between Blenrep and Tecvayli
Metric | Blenrep (belantamab mafodotin-blmf) | Tecvayli (teclistamab-cqyv) |
---|---|---|
Generic name | Belantamab mafodotin-blmf | Teclistamab-cqyv |
Indications | Treatment of relapsed or refractory multiple myeloma | Treatment of relapsed or refractory multiple myeloma |
Mechanism of action | Antibody-drug conjugate targeting B-cell maturation antigen (BCMA) | Bispecific antibody targeting BCMA and CD3 on T cells |
Brand names | Blenrep | Tecvayli |
Administrative route | Intravenous infusion | Intravenous infusion |
Side effects | Blurred vision, keratopathy, thrombocytopenia, infusion-related reactions, etc. | Cytokine release syndrome, infections, fatigue, musculoskeletal pain, etc. |
Contraindications | Ocular toxicity, pregnancy, breastfeeding | Severe hypersensitivity to teclistamab or its excipients |
Drug class | Antibody-drug conjugate | Bispecific antibody |
Manufacturer | GlaxoSmithKline (GSK) | Janssen Biotech, Inc. |
Efficacy
Blenrep (belantamab mafodotin-blmf) for Multiple Myeloma
Blenrep, with the active ingredient belantamab mafodotin-blmf, is a novel therapeutic agent approved for the treatment of multiple myeloma in patients who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. The efficacy of Blenrep was demonstrated in a pivotal multicenter, open-label, single-arm study known as DREAMM-2. Patients treated with Blenrep showed a clinically meaningful overall response rate (ORR), indicating a reduction in tumor burden in a significant proportion of the treated population.
The primary efficacy outcome measure was the ORR, which included partial response or better. The study results showed that a substantial percentage of heavily pre-treated patients achieved a partial response or better, which is notable given the refractory nature of their disease. The median duration of response (DOR) was also observed to be encouraging, suggesting that Blenrep can provide a period of disease control in patients with limited treatment options.
Tecvayli (teclistamab-cqyv) for Multiple Myeloma
Tecvayli, also known as teclistamab-cqyv, is a bispecific antibody that targets both CD3 on T cells and BCMA on myeloma cells, designed to redirect T cells to induce the killing of tumor cells. It has shown promise in clinical trials for the treatment of relapsed or refractory multiple myeloma. The efficacy of Tecvayli was evaluated in a phase 1/2 study, which demonstrated an ORR that was considered significant in patients who had previously undergone multiple lines of therapy, including those who were refractory to other standard treatments.
Patients treated with Tecvayli showed responses that were deep and durable, with a notable percentage achieving very good partial response or better. The median DOR, progression-free survival (PFS), and overall survival (OS) data from the study indicated that Tecvayli could offer a new therapeutic option for patients with advanced multiple myeloma. The effectiveness of Tecvayli highlights the potential of bispecific antibodies in the treatment landscape of multiple myeloma, particularly for patients who have exhausted other available therapies.
Regulatory Agency Approvals
Blenrep
Tecvayli
Access Blenrep or Tecvayli today
If Blenrep or Tecvayli are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us